Compare RDW & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RDW | WVE |
|---|---|---|
| Founded | 2020 | 2012 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | N/A | 2015 |
| Metric | RDW | WVE |
|---|---|---|
| Price | $8.22 | $17.15 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 16 |
| Target Price | $12.67 | ★ $29.94 |
| AVG Volume (30 Days) | 10.8M | ★ 13.7M |
| Earning Date | 11-05-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $296,147,000.00 | $109,230,000.00 |
| Revenue This Year | $11.62 | N/A |
| Revenue Next Year | $42.89 | $31.09 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 103.75 |
| 52 Week Low | $4.87 | $5.28 |
| 52 Week High | $26.66 | $21.73 |
| Indicator | RDW | WVE |
|---|---|---|
| Relative Strength Index (RSI) | 63.65 | 64.83 |
| Support Level | $6.32 | $15.23 |
| Resistance Level | $8.20 | $17.41 |
| Average True Range (ATR) | 0.79 | 2.02 |
| MACD | 0.24 | 0.14 |
| Stochastic Oscillator | 77.47 | 68.65 |
Redwire Corp is engaged in mission-critical space solutions and reliable components for the next-generation space economy. It assists its customers in solving the complex challenges of future space missions and industries. The company's space infrastructure offerings include a broad array of modern products and services, which have been enabling space missions. The company's plan enables it to combine decades of flight heritage with a culture creating new technologies that are the building blocks of space infrastructure for government and commercial customers.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.